UNSPSC 51142513: Rasagiline

This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 003N66TS6T, chemically known as 2,3-dihydro-n-2-propynyl-1h-inden-1-amine but generally known as rasagiline, which bears US NIH Compound Identifier 122316. European Medicines Agency schedules Rasagiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG.

UNSPSC 51142513 Rasagiline, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity in the dataset—Seminole County, Florida IFB 60459723LAS—solicits Naloxone and drug deactivation systems for community health support, not rasagiline. The mismatch suggests either a classification error in the county's tagging or opportunistic use of a broad pharmaceutical code that does not reflect actual purchasing patterns under this specific commodity line. State and local procurement offices do source pharmaceuticals through health departments, county community health programs, and special-purpose health districts, but rasagiline (a Parkinson's disease medication) typically appears in narrower demand signals tied to geriatric services, Medicaid formularies, or contracted pharmacy networks rather than direct commodity procurement.

Seminole County's Naloxone and drug deactivation systems procurement, posted June 30, 2026 with response due July 26, 2023, represents the only recent tracked opportunity under this code. The county sought 1,900 units of Naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to its Community Health Building in Sanford, Florida, with all shipping and delivery costs included in bid pricing. The IFB required electronic submission through the county's e-Procurement Portal, drug-free workplace certification, E-Verify compliance, and specified insurance coverage including workers' compensation and professional liability. The two-year initial contract with one-year renewal option included a three-month probationary termination clause and potential FEMA funding with associated federal compliance requirements. The scope divergence and limited recent activity suggest this code warrants close review before pursuit—the pharmaceutical taxonomy may not align with actual state and local buying patterns for rasagiline specifically.